Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder
Franklin R. Schneier, Jamie D. Feusner, Michael G. Wheaton, et al.
Journal of Psychiatric Research (2023) Vol. 161, pp. 364-370
Open Access | Times Cited: 46
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 22
Canalization and plasticity in psychopathology
Robin Carhart‐Harris, Shamil Chandaria, David Erritzøe, et al.
Neuropharmacology (2022) Vol. 226, pp. 109398-109398
Open Access | Times Cited: 66
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 932-942
Open Access | Times Cited: 47
Pattern breaking: a complex systems approach to psychedelic medicine
Inês Hipólito, Jonas Mago, Fernando E. Rosas, et al.
Neuroscience of Consciousness (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 38
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 733-748
Open Access | Times Cited: 33
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
Richard J. Zeifman, Anne Catherine Wagner, Candice M. Monson, et al.
Journal of Affective Disorders (2023) Vol. 334, pp. 100-112
Open Access | Times Cited: 29
Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
Kadi Tulver, Karl Kristjan Kaup, Ruben Laukkonen, et al.
Consciousness and Cognition (2023) Vol. 110, pp. 103494-103494
Open Access | Times Cited: 27
Effects of DMT on mental health outcomes in healthy volunteers
Christopher Timmermann, Richard J. Zeifman, David Erritzøe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder
Richard J. Zeifman, Hannes Kettner, Stephen Ross, et al.
European journal of psychotraumatology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Brandon Weiss, Leor Roseman, Bruna Giribaldi, et al.
International Journal of Mental Health and Addiction (2024) Vol. 22, Iss. 2, pp. 806-841
Open Access | Times Cited: 11
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Jacob S. Aday, David Horton, Gisele Fernandes‐Osterhold, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1517-1526
Closed Access | Times Cited: 9
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
David Erritzøe, Tommaso Barba, Kyle T. Greenway, et al.
EClinicalMedicine (2024), pp. 102799-102799
Open Access | Times Cited: 9
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
Tommaso Barba, Sarah Buehler, Hannes Kettner, et al.
BJPsych Open (2022) Vol. 8, Iss. 5
Open Access | Times Cited: 34
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Abigail E. Calder, Seline Mock, Nicole Friedli, et al.
European Neuropsychopharmacology (2023) Vol. 75, pp. 1-14
Open Access | Times Cited: 18
Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression
David Erritzøe, Tommaso Barba, Meg J. Spriggs, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 458-470
Open Access | Times Cited: 7
Psychedelics and the ‘inner healer’: Myth or mechanism?
Joseph Peill, M. Marguilho, David Erritzøe, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 417-424
Open Access | Times Cited: 7
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)
Max Wolff, Ricarda Evens, Lea J. Mertens, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 432-457
Open Access | Times Cited: 6
The neurobiology of aesthetic chills: How bodily sensations shape emotional experiences
Félix Schoeller, Abhinandan Jain, Diego A. Pizzagalli, et al.
Cognitive Affective & Behavioral Neuroscience (2024) Vol. 24, Iss. 4, pp. 617-630
Open Access | Times Cited: 5
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity
Débora Copa, David Erritzøe, Bruna Giribaldi, et al.
Journal of Affective Disorders (2024) Vol. 353, pp. 60-69
Closed Access | Times Cited: 4
Effects of psychedelics in older adults: A prospective cohort study
Hannes Kettner, Leor Roseman, Adam Gazzaley, et al.
American Journal of Geriatric Psychiatry (2024) Vol. 32, Iss. 9, pp. 1047-1059
Closed Access | Times Cited: 4
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Ronit Kishon, Nadav Liam Modlin, Yael M. Cycowicz, et al.
npj Mental Health Research (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
A qualitative analysis of the psychedelic mushroom come-up and come-down
Ari Brouwer, Joshua K. Brown, Earth Erowid, et al.
npj Mental Health Research (2025) Vol. 4, Iss. 1
Open Access
Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution
S. Adamczyk, Małgorzata Paczyńska, Anastasia Ruban, et al.
Journal of Psychoactive Drugs (2025), pp. 1-12
Closed Access
Page 1 - Next Page

Scroll to top